Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer

Web Exclusives - FDA Approvals

On October 12, 2021, the FDA approved the combination of abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20%, as determined by an FDA-approved test. Abemaciclib is the first CDK 4/6 inhibitor to receive FDA approval for adjuvant treatment of breast cancer.

On the same day, the FDA also approved the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay as a companion diagnostic test for selecting appropriate patients for this combination therapy.

This approval was based on the monarchE study, a randomized, open-label, 2-cohort multicenter clinical trial. The study included women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer and clinical and pathological features consistent with a high risk for disease recurrence. Patients were randomized in a 1 to 1 ratio to 2 years of abemaciclib plus their physician’s choice of endocrine therapy or to endocrine therapy alone.

The primary end point was invasive disease-free survival (IDFS). In the 2003 patients with high risk for disease recurrence and Ki-67 score ≥20%, the use of abemaciclib plus endocrine therapy showed significant improvement in IDFS (hazard ratio, 0.626; 95% confidence interval [CI], 0.488-0.803; P = .0042) versus endocrine therapy alone. At 36 months, the IDFS was 86.1% (95% CI, 82.8-88.8) with abemaciclib plus endocrine therapy compared with 79.0% (95% CI, 75.3-82.3) with endocrine therapy alone. The overall survival data were not mature at the time of the analysis.

The most common (≥20%) side effects were diarrhea, infections, neutropenia, fatigue, leukopenia, nausea, anemia, and headache.

Related Items
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
Web Exclusives published on July 29, 2022 in FDA Approvals
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
Web Exclusives published on July 22, 2022 in FDA Approvals
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
Web Exclusives published on July 19, 2022 in FDA Approvals
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
Web Exclusives published on July 19, 2022 in FDA Approvals
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
Web Exclusives published on May 26, 2022 in FDA Approvals
Last modified: February 16, 2022
Copyright © Engage Healthcare Communications, LLC. All rights reserved.